Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 147

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 147
---
 neither an accelerated filer nor a large accelerated filer (as such terms are defined under U.S. federal
securities laws) and therefore not required to obtain an attestation report from our independent registered public accounting firm on
the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, we nevertheless
expect to incur additional legal, accounting, financial and other costs associated with being a public company that is not an EGC, including
mandatory adoption of new accounting pronouncements. We may also incur costs associated with compliance with the requirements of additional
disclosure requirements, including Section 404(b) of the Sarbanes-Oxley Act in the event that we determine that we have become
an accelerated filer or large accelerated filer.

Further, investors may find
our securities less attractive because of our reliance on the foregoing exemption from Section 404(b) of the Sarbanes-Oxley
Act, as well as any other exemptions available to us under U.S. federal securities laws. This could contribute to a less active trading
market for our securities and prices of the securities may be more volatile or decline.

<div align='center'>77</div>

RISKS RELATED TO DIAMIR’S BUSINESS AND OPERATIONS

Unless otherwise stated, all references to “DiamiR,” and similar designations under this section, Risks Related to DiamiR’s Business and Operations, refer to DiamiR Biosciences Corp, a Delaware corporation, and its wholly-owned subsidiary DiamiR, LLC a private Delaware limited liability company.

Risks Related to DiamiR’s Business and Operations

DiamiR may not complete the Merger or may be delayed in completing the Merger.

The DiamiR Merger is at the very early stages and will be subject to
the completion of satisfactory due diligence, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other
third-party approvals and the fulfillment of customary closing conditions. There is no certainty and DiamiR can provide no assurances
that the parties will successfully negotiate and enter into a definitive agreement, or that the DiamiR merger will be consummated on the
terms or timeframe currently contemplated, or at all. If the DiamiR merger is not completed as contemplated, DiamiR could suffer adverse
consequences, including the loss of investor confidence, volatility and a significant decrease in the market prices of its securities
and reputational harm. In addition, any delay in completing the